Oppenheimer Reiterates Outperform on Tyra Biosciences, Lowers Price Target to $40
Oppenheimer analyst Mazahir Alimohamed reiterates Tyra Biosciences (NASDAQ:TYRA) with a Outperform and lowers the price target from $50 to $40.
An expert analyst still likes Tyra Biosciences but thinks it is worth less money now. When experts lower price targets, watch if the company's plans changed or if the whole market got shakier.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.